论文部分内容阅读
目的研究claudin-3和β-连环素(β-catenin)蛋白在卵巢交界性肿瘤(borderline ovarian tumors,BOTs)组织中的表达及临床病理意义。方法采用免疫组织化学SP法检测claudin-3和β-catenin蛋白在69例BOTs组织中的表达,并与其在17例正常卵巢组织、31例卵巢上皮性良性肿瘤、39例卵巢上皮性恶性肿瘤组织中的表达进行比较。结果BOTs组织中claudin-3蛋白的阳性表达率(59.4%,41/69)低于卵巢癌组织中的阳性表达率(89.7%,35/39),而高于良性肿瘤及正常卵巢组织中的表达率(22.6%,7/31;5.9%,1/17),差异均有统计学意义(P<0.01);正常卵巢组织与良性肿瘤相比,差异无统计学意义(P>0.05)。BOTs组织中β-catenin蛋白的阳性表达率(52.2%,36/69)低于卵巢癌组织中的阳性表达率(84.7%,33/39),而高于良性肿瘤及正常卵巢组织中的表达率(29.0%,9/31;11.8%,2/17),差异均有统计学意义(P<0.01或P<0.05);而正常卵巢组织与良性肿瘤相比,差异无统计学意义(P>0.05)。Claudin-3和β-catenin蛋白的表达与BOTs患者的临床病理分期以及腹腔有无种植相关(P<0.05),而与组织学类型和患者年龄无关(P>0.05)。Claudin-3与β-catenin在BOTs组织中的表达呈正相关(r=0.439,P=0.000)。结论 Claudin-3与β-catenin在BOTs的发生、发展中可能起着协同作用,对其进行联合检测有助于BOTs的诊断和治疗。
Objective To study the expression and clinical significance of claudin-3 and β-catenin proteins in borderline ovarian tumors (BOTs). Methods The expressions of claudin-3 and β-catenin protein in 69 BOTs tissues were detected by immunohistochemical SP method and compared with those in 17 normal ovarian tissues, In the expression of comparison. Results The positive rate of claudin-3 protein expression in BOTs was lower than that in ovarian cancer (89.7%, 35/39) (59.4%, 41/69), but higher than that in benign tumors and normal ovarian tissues The expression rate was significantly higher than that in benign tumors (22.6%, 7/31; 5.9%, 1/17) (P <0.01). There was no significant difference between normal ovarian tissues and benign tumors (P> 0.05). The positive expression rates of β-catenin protein in BOTs tissues (52.2%, 36/69) were lower than those in ovarian cancer tissues (84.7%, 33/39), but higher than that in benign tumors and normal ovarian tissues (P <0.01 or P <0.05), while there was no significant difference between normal ovarian tissue and benign tumor (P> 0.05). The difference was statistically significant (P <0.01 or P < > 0.05). The expression of Claudin-3 and β-catenin was correlated with the clinicopathological stage and the presence or absence of intraperitoneal implantation of BOTs (P <0.05), but not with histological type and patient age (P> 0.05). The expression of Claudin-3 and β-catenin in BOTs tissues were positively correlated (r = 0.439, P = 0.000). Conclusion Claudin-3 and β-catenin may play synergistic roles in the pathogenesis and development of BOTs. Combined detection of Claudin-3 and β-catenin may be helpful for the diagnosis and treatment of BOTs.